Oligoribonucleotide and ribozyme analogs with terminal 3′—3′ and/or 5′—5′ linkages

US6420546B1 · kind B1 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Heinz-Hartmut Seliger · Neu-Ulm, DE
• Flavio Ramalho Ortigao · Ulm, DE
• Hannelore Rösch · Erbach, DE
• Rudi Rösch · Erbach, DE
• Bernd Krist · Ulm, DE

Key dates

• Filing date: Apr 14, 1998
• Grant date: Jul 16, 2002
• Expiry date: Apr 14, 2018

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to oligoribonucleotide analogs with terminal 3′—3′ and/or 5′—5′ internucleotide linkages. This modification stabilizes the molecules altered in this way, including ribozymes, without adversely altering their properties, including, where appropriate, catalytic activities.